glp-1 and gip receptor agonist The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Understand GLP-1/GIP Dual Agonist Tirzepatide
Description
doi: 10.1210/en.2010-0289 [DOI] [PMC free article] [PubMed] [Google Scholar] 43.Knauf C, Cani PD, Ait-Belgnaoui A, et al
They, therefore, have favourable effect on glucose metabolism and lead to significant caloric intake reduction and resultant weight reduction, usually in the vicinity of 3 - 8 kg depending on the dose and agent used
Diamant M, Van Gaal L, Guerci B, et al
3 This central nervous system effect is crucial for weight loss associated with these medications
The best option depends on the patients medical history, weight loss goals, reflux symptoms, and overall health
